KURA
Kura Oncology, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -16.8% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 85 | +3 | 46.85M | $513.57M | +7 | −4 |
| Q1 2026 | 85 | 0 | 43.54M | $354.05M | +5 | −5 |
| Q4 2025 | 85 | 0 | 47.00M | $488.20M | +1 | −1 |
| Q3 2025 | 15 | -1 | 31.70M | $280.57M | — | −1 |
| Q2 2025 | 13 | 0 | 25.43M | $146.75M | — | — |
| Q1 2025 | 10 | 0 | 9.58M | $63.25M | — | — |
| Q4 2024 | 10 | -1 | 11.52M | $100.37M | +1 | −2 |
| Q3 2024 | 10 | 0 | 4.92M | $96.24M | +1 | −1 |
| Q2 2024 | 10 | — | 4.04M | $83.12M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.28M | -1.9% | $21.66M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Millennium Management ✦ | 1.81M | -23.6% | $11.94M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.80M | +1.1% | $11.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.80M | +1.1% | $11.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 760.33K | +407.8% | $5.02M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 760.33K | +407.8% | $5.02M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 760.33K | +407.8% | $5.02M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 760.33K | +407.8% | $5.02M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 760.33K | +407.8% | $5.02M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 532.61K | -10.9% | $3.52M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 418.99K | -63.6% | $2.77M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 418.99K | -63.6% | $2.77M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 394.24K | -60.0% | $2.60M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 394.24K | -60.0% | $2.60M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Marshall Wace ✦ | 392.05K | -58.7% | $2.59M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Marshall Wace ✦ | 392.05K | -58.7% | $2.59M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 158.99K | -4.3% | $1.05M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 31.72K | +13.0% | $210,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 217 holders, 84.35M shares, $677.88M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · President and CEO · 100.00K sh @ 12.39 · $1.24M
Officer, Director · President and CEO · 100.00K sh @ 11.12 · $1.11M
Open-market sales (S)
Officer · 4.34K sh · $51,663
Officer · 31.49K sh · $397,681
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology